Published in Schweiz Med Wochenschr on September 18, 1993
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2011) 5.30
Natural infection of man with group A streptococci. Levels; restriction in class, subclass, and type; and clonal appearance of polysaccharide-group-specific antibodies. Scand J Immunol (1976) 2.78
Short-term effects of atorvastatin on C-reactive protein. Eur Heart J (2002) 2.15
Is pretreatment with Beta-blockers beneficial in patients with acute coronary syndrome? Cardiology (2009) 2.08
Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation (1996) 2.05
The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol (1994) 2.04
Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med (1988) 1.66
Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med (1986) 1.60
Antihypertensive treatment and serum lipoproteins. J Hypertens (1985) 1.54
Effect of thyroid function on concentrations of lipoprotein(a) Clin Chem (1993) 1.48
Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM. Diabet Med (1997) 1.47
Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents. Lancet (1993) 1.47
Impaired response of atrial natriuretic factor to high salt intake in persons prone to hypertension. N Engl J Med (1988) 1.46
Simple point-of-care risk stratification in acute coronary syndromes: the AMIS model. Heart (2008) 1.45
Changes of immunoregulatory cells induced by psychological and physical stress: relationship to plasma catecholamines. Clin Exp Immunol (1984) 1.45
Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I. Diabetologia (1993) 1.45
Calcium binding to fluorescent calcium indicators: calcium green, calcium orange and calcium crimson. Biochem Biophys Res Commun (1991) 1.44
Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J (1996) 1.42
Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res (2000) 1.42
The impact of statin treatment on presentation mode and early outcomes in acute coronary syndromes. Cardiology (2007) 1.40
Increased central body fat deposition precedes a significant rise in resting blood pressure in male offspring of essential hypertensive parents: a 5 year follow-up study. J Hypertens (2001) 1.40
Comparative effects of haemodialysis and haemofiltration on plasma atrial natriuretic peptide. Nephrol Dial Transplant (1989) 1.39
Expression of cell adhesion molecule T-cadherin in the human vasculature. Histochem Cell Biol (2001) 1.38
[Lipoprotein(a) and hemostasis activation markers in angina pectoris]. Dtsch Med Wochenschr (1995) 1.38
Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-beta1 and TGF-beta3. Am J Physiol (1999) 1.36
Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy. N Engl J Med (1984) 1.34
Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest (1994) 1.33
Trigeminal cardiac reflex: new thinking model about the definition based on a literature review. Medicine (Baltimore) (2015) 1.30
Kinetics of calcium binding to fluo-3 determined by stopped-flow fluorescence. Biochem Biophys Res Commun (1989) 1.30
Six S100 genes are clustered on human chromosome 1q21: identification of two genes coding for the two previously unreported calcium-binding proteins S100D and S100E. Proc Natl Acad Sci U S A (1993) 1.30
Sodium-volume factor, cardiovascular reactivity and hypotensive mechanism of diuretic therapy in mild hypertension associated with diabetes mellitus. Am J Med (1979) 1.30
A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42-q43. Hum Mol Genet (1995) 1.29
Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta (1996) 1.29
High prevalence of cardiovascular risk factors in the Seychelles (Indian Ocean). Arterioscler Thromb (1991) 1.27
Metabolic properties of human IgA subclasses. Clin Exp Immunol (1973) 1.26
Effect on aging on plasma renin and aldosterone in normal man. Kidney Int (1975) 1.23
Effects of antihypertensive therapy on serum lipoproteins. Hypertension (1983) 1.19
Alpha and beta adrenergic blockade with orally administered labetalol in hypertension. Studies on blood volume, plasma renin and aldosterone and catecholamine excretion. Am J Cardiol (1978) 1.19
Different translocation of three distinct PKC isoforms with tumor-promoting phorbol ester in human platelets. Biochem Biophys Res Commun (1991) 1.17
Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest (1986) 1.13
Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A (1996) 1.12
Body sodium-blood volume state, aldosterone, and cardiovascular responsiveness after calcium entry blockade with nifedipine. Kidney Int (1985) 1.12
Curable hypertension with unilateral hydronephrosis. Studies on the role of circulating renin. Ann Intern Med (1977) 1.11
Long-term cimetidine in children with cystic fibrosis: a randomized double-blind study. Pediatr Res (1984) 1.11
Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. Kidney Int (1992) 1.09
Calcium and magnesium binding to rat parvalbumin. Eur J Biochem (1994) 1.09
Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis (2005) 1.09
The vasodilator potency of atrial natriuretic peptide in man. Circulation (1987) 1.07
Effects of nitrendipine and other calcium antagonists on glucose metabolism in man. J Cardiovasc Pharmacol (1984) 1.07
Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. Am J Med (1991) 1.06
Enhancement of calcium influx in human platelets by CGP 28392, a novel dihydropyridine. Biochem Biophys Res Commun (1984) 1.06
Methicillin nephritis. Medicine (Baltimore) (1977) 1.05
Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. J Am Coll Cardiol (1986) 1.05
Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest (1992) 1.04
Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am J Hypertens (2001) 1.03
Increased ratio between serum beta- and alpha-lipoproteins during diuretic therapy: an adverse effect? Clin Sci Mol Med Suppl (1978) 1.03
Blood pressure effects of acute hypercalcemia. Studies in patients with chronic renal failure. Ann Intern Med (1972) 1.02
S100 alpha, CAPL, and CACY: molecular cloning and expression analysis of three calcium-binding proteins from human heart. Biochemistry (1992) 1.01
Sodium, renin, aldosterone, catecholamines, and blood pressure in diabetes mellitus. Kidney Int (1977) 1.01
Increased lipoprotein(a) levels are not a steady prothrombotic defect. Blood (2001) 1.00
Apoproteins and lipids as discriminators of severity of coronary heart disease. Atherosclerosis (1980) 1.00
Autonomic function tests as related to age and gender in normal man. Klin Wochenschr (1986) 1.00
Atrial natriuretic peptide protects against acute ischemic renal failure in the rat. J Clin Invest (1987) 0.99
Epidemiologic variables and outcome of 1972 young patients with acute myocardial infarction. Data from the GISSI-2 database. Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). Arch Intern Med (1997) 0.99
Generation of the isoprostane 8-epi-prostaglandin F2alpha in vitro and in vivo via the cyclooxygenases. J Pharmacol Exp Ther (1997) 0.99
Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev (2001) 0.99
Acute hypercalcemic hypertension in man: role of hemodynamics, catecholamines, and renin. Kidney Int (1981) 0.99
Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med (1971) 0.98
Plasma renin and blood pressure during treatment with methyldopa. Am J Cardiol (1974) 0.98
Nerve growth factor induces mast cell degranulation without changing intracellular calcium levels. FEBS Lett (1986) 0.97
Virus infections in renal transplant recipients. Z Immunitatsforsch Exp Klin Immunol (1975) 0.97
MRI in Cockayne syndrome type I. Neuroradiology (1989) 0.97
Effect of sodium intake on plasma catecholamines in normal subjects. J Clin Endocrinol Metab (1979) 0.96
Studies on retinal microangiopathy and coronary macroangiopathy in rats with streptozotocin-induced diabetes. Virchows Arch B Cell Pathol Incl Mol Pathol (1981) 0.95
Calcitonin gene-related peptide is a stimulator of renin secretion. J Clin Invest (1988) 0.95
Increase in circulating insulin induced by atrial natriuretic peptide in normal humans. J Cardiovasc Pharmacol (1987) 0.95
Antibodies against lipoproteins in man. Occurrence and biological significance. Klin Wochenschr (1975) 0.94
Enhanced exercise-induced rise of aldosterone and vasopressin preceding mountain sickness. J Appl Physiol (1985) (1991) 0.94
Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med (1984) 0.94
Atrial natriuretic peptide in acute mountain sickness. J Appl Physiol (1985) (1988) 0.93
Effects of tyramine on blood pressure and plasma catecholamines in normal and hypertensive subjects. Klin Wochenschr (1982) 0.93
Human and murine phosphorycholine-binding immunoglobulins: conserved subgroup and first hypervariable region of heavy chains. Proc Natl Acad Sci U S A (1976) 0.93
Insulin, insulin sensitivity and hypertension. J Hypertens (1990) 0.92
Factors influencing the hypotensive effects of calcium antagonists. Hypertension (1983) 0.92
Plasma renin activity in patients with coarctation of the aorta. A comment of the pathogenesis prestenotic hypertension. Circulation (1969) 0.92
[The effect of diuretic therapy on serum lipoproteins: an undesirable effect?]. Schweiz Med Wochenschr (1979) 0.91
Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol (1994) 0.91
Characterization of the human and mouse cDNAs coding for S100A13, a new member of the S100 protein family. Biochem Biophys Res Commun (1996) 0.91
Hypertension associated with tumors adjacent to renal arteries. Am J Med (1969) 0.91
Age versus urinary sodium for judging renin, aldosterone, and catecholamine levels: studies in normal subjects and patients with essential hypertension. Kidney Int (1978) 0.91
Arterial vasodilator, systemic and coronary hemodynamic effects of nisoldipine in congestive heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol (1987) 0.91
Relation of arterial pressure with body sodium, body potassium and plasma potassium in essential hypertension. Clin Sci (Lond) (1982) 0.90
Stimulation of renin secretion by potassium-channel activation with cromakalim. Eur J Clin Pharmacol (1989) 0.90
Norepinephrine clearance and pressor effect in normal and hypertensive man. Klin Wochenschr (1980) 0.90
Myocardial tissue characterization in heart failure by real-time integrated backscatter. Eur J Ultrasound (1999) 0.90
LDL induces intracellular signalling and cell migration via atypical LDL-binding protein T-cadherin. Mol Cell Biochem (2005) 0.90
Increased serum low-density lipoprotein cholesterol in men treated short-term with the diuretic chlorthalidone. Metabolism (1980) 0.90
Hypocholesterolemia in idiopathie hirsutism. N Engl J Med (1973) 0.90
Ca2+ as messenger of 5HT2-receptor stimulation in human blood platelets. Naunyn Schmiedebergs Arch Pharmacol (1984) 0.90
Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res (1998) 0.90
Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol (1991) 0.89